Navigation Links
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Date:5/30/2009

e of 20 mg/m2 on days 1 and 2, followed by 36 mg/m2 on days 8, 9 and 15, 16 over a 28-day cycle. The ongoing Phase 2 clinical is intended to assess the safety and efficacy of single-agent carfilzomib in patients with recurrent or advanced solid tumors. Enrolled patients are stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer. The open-label, multi-center clinical trial is a two-stage design, with pre-determined criteria for continuation after an initial cohort of patients have been treated.

In the Phase 1b trial, carfilzomib demonstrated activity in advanced solid tumors, with partial responses observed in renal cancer and small cell lung cancer patients. A total of 55 patients are currently evaluable for response in the Phase 1b and Phase 2 clinical studies.

Carfilzomib was generally well tolerated. The most common adverse events include fatigue headache, nausea, diarrhea, constipation and anemia. Notably, there were no incidents of Grade 3/4 neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. To date, 65 patients in the Phase 1b and Phase 2 clinical trials have received 154.5 cycles of carfilzomib.

"We are genuinely excited by growing clinical evidence for carfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. Carfilzomib is well tolerated and active across a number of different tumor types in patients with advanced cancers," said Michael Kauffman, M.D., Ph.D., Chief Medical Officer of Proteolix. "We are committed to expeditiously demonstrating the treatment benefits of carfilzomib in multiple treatment settings. We expect to complete the first stage of our Phase 2 trial in advanced solid tumors and our late-stage clinical studies of carfilzomib in multiple myeloma, and we are actively planning a Phase 3 clinical trial in relapsed multiple
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
2. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
7. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...TICK, Mass., Nov. 6 Bost...unced that it has reached an agreement in principl...d to product advisories issued by its Guidant subs...ales occurred prior to Boston Scientific,s 2006 ac...previously disclosed an investigation by the U.S. ...
(Date:11/6/2009)...N DIEGO, Nov. 6 Ardea Bi...company focused on the development of small-molecu...and human immunodeficiency virus (HIV), today repo...for the third quarter and nine months ended Septem...om/cgi-bin/prnh/20091104/ARDEALOGO ) ,, "Since ...
(Date:11/6/2009)...LANTA, Nov. 6 GeoVax La..."the Company"), an Atlanta-based, biopharmaceutica...aused by HIV-1 (Human Immunodeficiency Virus) and ... quarter 2009 financial results and provided an op...sident and Chief Executive Officer commented, "We ...
Breaking Medicine Technology:Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 1Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 2Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 3Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 4Working Out in the Garden 50717 1On Memory Older Americans Outsmart the English 50713 1On Memory Older Americans Outsmart the English 50713 2
(Date:11/8/2009)...lutions is pleased to announce that it has been su...or ReSound who recently received an award on the $...ward includes not only the Veterans Administration...eral agencies. , New York...ns is pleased to announce that it has been success...
(Date:11/8/2009)...battle is won," said Dr. Charmaine Yoest. ,, W...vote of 240-194, the Stupak-Ellsworth-Pitts-Kaptur...bortion mandates and funding in HR 3962 passed on ...ction President and CEO Dr. Charmaine Yoest said, ...e pro-life Americans across this country who have ...
(Date:11/8/2009)...SNewswire/ -- The following was released today by ...ta Nex. ,, Mr. Terry and his associates from a...-killing by abortion out of any health care bill f...t first step to victory -- a touchdown in the firs...f us. Our rejoicing must be tempered by reality. T...
(Date:11/7/2009)...SNewswire/ -- Karen Ignagni, President and CEO of ...the following statement today on House passage of ...mprehensive health care reform, and we have contri...verhaul of how health insurance is provided. Earli...mination of pre-existing condition exclusions, no ...
(Date:11/7/2009)...Calling this a "defining moment" for the American ...mes Rohack, M.D., today addressed medical students...specialty societies at the opening of the AMA,s se...em reform will top the agenda. ,, (Logo: http... ) ,, "Over the next 72 hours, this AMA House o...
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2
...arhers have found from a long-term study that men ...s more likely to eventually develop Parkinson's di... of Biostatistics and Statistics at the University...tipation is defined as less than one bowel movemen...
...sure to sunlight may increase the risk of developi... a cloudy or opaque area in the normally transpare...vents light rays from passing through the lens and...d people who were exposed to high levels of sunlig...
...of the leading pharmaceutical industries, Ranbaxy ...-market Ranbaxy’s once-a-day formulation of Ciprof...g Controller General of India’s (DCGIs) approval f... around Rs 310 crore. // Ciprofloxacin is the...
...ing men are at greater risk of developing heart di...earchers.Their findings were published in the Arch...ng relationship" between coronary heart disease an...9% increased chance of getting heart disease. Comp...
...he biggest breakthrough, the incidence of the dise...ation of drugs that keeps blood pressure in check.... years in many countries showed that strokes were ... and heart attacks and consequently deaths. The dr...
...e are many grueling and expensive options to explo... of it being Acupuncture. According to an art... are particularly favour acupuncture because they ...s, hundreds are lost with each menstrual cycle and...
Other Medicine News:
AxSYM
ADVIA Centaur Immunoassay System
...linical system combines market-leading chemistry a...y testing capabilities, innovative data management...m. After tests are performed, critical results are...nce. If reflex tests are necessary based on user d...
Miltex frazier ferguson suction tubes
Medicine Products: